Articles producció científica> Medicina i Cirurgia

Three-Month Outcomes in Cancer Patients with Superficial or Deep Vein Thrombosis in the Lower Limbs: Results from the RIETE Registry

  • Identification data

    Identifier: imarina:9320310
  • Authors:

    Debourdeau, P
    Bertoletti, L
    Font, C
    López-Núñez, JJ
    Gómez-Cuervo, C
    Mahe, I
    Otero-Candelera, R
    Adarraga, MD
    López-Miguel, P
    Monreal, M
  • Others:

    Author, as appears in the article.: Debourdeau, P; Bertoletti, L; Font, C; López-Núñez, JJ; Gómez-Cuervo, C; Mahe, I; Otero-Candelera, R; Adarraga, MD; López-Miguel, P; Monreal, M
    Department: Medicina i Cirurgia
    URV's Author/s: Porras Ledantes, Jose Antonio
    Keywords: Venous thromboembolism Thrombophlebitis Superficial vein thrombosis Prognosis Heparin Fondaparinux Deep venous thrombosis Cancers Anticoagulants
    Abstract: Background: The clinical characteristics and outcomes of cancer patients with lower-limb isolated superficial vein thrombosis (SVT) have not been consistently evaluated. Methods: We used data in the RIETE registry to compare the clinical characteristics and 90-day outcomes for patients with: (1) active cancer and lower-limb SVT; (2) active cancer and lower-limb deep vein thrombosis (DVT); (3) lower-limb SVT without cancer. The primary outcomes included subsequent symptomatic SVT, DVT or pulmonary embolism (PE). Secondary outcomes were major bleeding and death. Results: From March 2015 to April 2021, there were 110 patients with cancer and SVT, 1695 with cancer and DVT, and 1030 with SVT but no cancer. Most patients in all subgroups (93%, 99% and 96%, respectively) received anticoagulants, while those with SVT received lower daily doses of low-molecular-weight heparin (114 +/- 58, 163 +/- 44, and 106 +/- 50 IU/kg, respectively). During the first 90 days, 101 patients (3.6%) developed subsequent VTE (PE 47, DVT 41, SVT 13), whereas 72 (2.5%) had major bleeding and 282 (9.9%) died. Among the three groups, 90-day events were, respectively: VTE at rates of 7.3%, 4.0% and 2.4%; major bleeding at rates of 2.7%, 3.9% and 0.3%; mortality at rates of 8.2%, 16% and 0.3%. Between D90 and D180, only one SVT recurrence and one death occurred in SVT cancer patients. In multivariable analysis, cancer was associated with subsequent VTE (HR = 2.04; 1.15-3.62), while initial presentation as SVT or DVT were not associated with a different risk. Conclusions: The risk for subsequent VTE (including symptomatic SVT, DVT or PE) was similar in cancer patients with isolated SVT than in those with isolated DVT.
    Thematic Areas: Oncology Medicina iii Cancer research
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    Author's mail: joseantonio.porras@urv.cat
    Author identifier: 0000-0001-6418-1822
    Record's date: 2023-12-02
    Papper version: info:eu-repo/semantics/publishedVersion
    Link to the original source: https://www.mdpi.com/2072-6694/15/7/2034
    Licence document URL: http://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: Cancers. 15 (7):
    APA: Debourdeau, P; Bertoletti, L; Font, C; López-Núñez, JJ; Gómez-Cuervo, C; Mahe, I; Otero-Candelera, R; Adarraga, MD; López-Miguel, P; Monreal, M (2023). Three-Month Outcomes in Cancer Patients with Superficial or Deep Vein Thrombosis in the Lower Limbs: Results from the RIETE Registry. Cancers, 15(7), -. DOI: 10.3390/cancers15072034
    Article's DOI: 10.3390/cancers15072034
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2023
    Publication Type: Journal Publications
  • Keywords:

    Cancer Research,Oncology
    Venous thromboembolism
    Thrombophlebitis
    Superficial vein thrombosis
    Prognosis
    Heparin
    Fondaparinux
    Deep venous thrombosis
    Cancers
    Anticoagulants
    Oncology
    Medicina iii
    Cancer research
  • Documents:

  • Cerca a google

    Search to google scholar